HESTER BIOSCIENCES LTD (HESTERBIO) financials

HESTER BIOSCIENCES LTD (HESTERBIO) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1987, Hester Biosciences Ltd is one of India’s leading animal healthcare companies and a major manufacturer of poultry and animal vaccines, including a leading position in PPR and Goat Pox vaccines.[1]

Market Cap: ₹1,819Cr.
Current Price: ₹2,129
Stock P/E: 33.9
ROE: 13.0%
ROCE: 15.5%
Book Value: ₹453
Dividend Yield: 0.52%
52W High / Low: ₹2,684/1,239

In Jun 2026, HESTER BIOSCIENCES LTD (HESTERBIO) reported sales ₹73 Cr and net profit ₹15 Cr.

Annual TTM: sales ₹301 Cr, net profit ₹59 Cr.

Shareholding: Promoters 53.73% (Jun 2026), FIIs 0.31% (Jun 2026), DIIs 0.00% (Jun 2026), Public 45.95% (Jun 2026), No. of Shareholders 11,961% (Jun 2026).

HESTERBIO quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	74	63	77	63	65	70	94	73
Expenses	59	54	63	51	53	54	62	48
Operating Profit	15	9	14	12	12	17	31	24
OPM %	20%	14%	18%	20%	18%	24%	34%	34%
Other Income	1	1	1	1	1	1	11	2
Interest	1	2	1	1	1	1	4	1
Depreciation	2	2	2	2	2	2	4	5
Profit before tax	12	6	11	10	10	15	35	20
Tax %	25%	32%	16%	24%	27%	27%	24%	26%
Net Profit	9	4	10	8	7	11	26	15
EPS in Rs	10.98	5.22	11.33	9.22	8.48	12.54	31.01	17.29
Raw PDF	—	—	—	—	—	—	—	—

HESTERBIO profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	169	208	219	254	285	286	292	301
Expenses	117	136	159	199	238	235	219	217
Operating Profit	53	72	61	55	47	51	73	84
OPM %	31%	35%	28%	22%	17%	18%	25%	28%
Other Income	3	-4	5	5	4	4	14	15
Interest	5	4	2	6	5	5	7	8
Depreciation	9	10	10	10	10	9	10	13
Profit before tax	41	55	53	44	37	42	70	79
Tax %	24%	27%	26%	26%	26%	24%	25%	—
Net Profit	31	40	40	32	27	32	52	59
EPS in Rs	36.70	46.90	46.46	38.02	31.93	37.43	61.24	69.32
Dividend Payout %	18%	21%	22%	21%	19%	19%	18%	—

HESTERBIO balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	9	9	9	9	9	9	9	9
Reserves	171	195	229	260	284	304	331	377
Borrowings	38	48	16	122	164	134	104	75
Other Liabilities	23	26	29	34	89	103	103	97
Total Liabilities	240	277	282	424	546	550	546	557
Fixed Assets	101	96	87	84	108	103	105	288
CWIP	0	1	4	82	149	171	183	9
Investments	28	41	44	65	65	65	65	64
Other Assets	111	139	148	194	224	210	193	196
Total Assets	240	277	282	424	546	550	546	557

HESTERBIO cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	36	26	41	16	33	43	64	51
Cash from Investing Activity	-25	-21	-4	-111	-72	-21	-19	-2
Cash from Financing Activity	-20	-1	-41	95	41	-24	-46	-48
Net Cash Flow	-9	3	-4	0	3	-2	-1	0
Free Cash Flow	25	18	37	-75	-39	21	44	34
CFO/OP	76%	71%	76%	53%	75%	114%	144%	89%

HESTERBIO shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	53.73%	53.73%	53.73%	53.73%	53.73%	53.73%	53.73%	53.73%
FIIs	0.61%	0.59%	0.87%	0.51%	0.53%	0.52%	0.38%	0.31%
DIIs	0.00%	0.02%	0.02%	0.02%	0.00%	0.01%	0.00%	0.00%
Public	45.66%	45.65%	45.38%	45.73%	45.73%	45.75%	45.88%	45.95%
No. of Shareholders	11,538	11,473	11,853	11,810	12,260	12,603	12,373	11,961

HESTERBIO key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	70	96	80	95	118	110	103	115
Inventory Days	511	754	390	404	362	251	228	267
Days Payable	85	170	96	63	131	109	127	92
Cash Conversion Cycle	496	681	374	436	349	252	204	290
Working Capital Days	123	129	182	149	106	130	110	117
ROCE %	31%	20%	25%	17%	12%	9%	11%	16%

HESTERBIOUpdated 13 Oct 2026, 17:39

Hester Biosciences Ltd

HESTERBIOUpdated 13 Oct 2026, 17:39

Market Cap

₹1,819Cr.

Current Price

₹2,129

High / Low

₹2,684/1,239

Stock P/E

33.9

ROE13.0%

ROCE15.5%

Book Value₹453

Face Value₹10.0

Dividend Yield0.52%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	80	1	69	1	3	9	26	6	7.61
Sep 2023	66	1	54	1	3	9	26	7	7.97
Dec 2023	66	1	54	1	3	9	25	6	7.62
Mar 2024	73	1	60	1	2	10	27	7	8.73
Jun 2024	73	1	60	1	2	11	25	8	9.91
Sep 2024	74	1	59	1	2	12	25	9	10.98
Dec 2024	63	2	54	1	2	6	32	4	5.22
Mar 2025	77	1	63	1	2	11	16	10	11.33
Jun 2025	63	1	51	1	2	10	24	8	9.22
Sep 2025	65	1	53	1	2	10	27	7	8.48
Dec 2025	70	1	54	1	2	15	27	11	12.54
Mar 2026	94	4	62	11	4	35	24	26	31.01
Jun 2026	73	1	48	2	5	20	26	15	17.29

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	90	4	64	3	5	19	26	14	16.45
Mar 2016	101	4	67	1	6	25	23	19	22.59
Mar 2017	123	3	82	1	6	33	25	25	29.32
Mar 2018	135	2	85	2	5	44	30	31	35.92
Mar 2019	171	4	103	3	8	60	27	44	51.55
Mar 2020	169	5	117	3	9	41	24	31	36.7
Mar 2021	208	4	136	-4	10	55	27	40	46.9
Mar 2022	219	2	159	5	10	53	26	40	46.46
Mar 2023	254	6	199	5	10	44	26	32	38.02
Mar 2024	285	5	238	4	10	37	26	27	31.93
Mar 2025	286	5	235	4	9	42	24	32	37.43
Mar 2026	292	7	219	14	10	70	25	52	61.24
TTM	301	8	217	15	13	79	—	59	69.32

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	53.73%
FIIs	0.31%
Public	45.95%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public
Sep 2023	53.73%	0.42%	0%	—	45.84%
Dec 2023	53.73%	0.43%	0%	—	45.83%
Mar 2024	53.73%	0.43%	0%	—	45.84%
Jun 2024	53.73%	0.52%	0%	—	45.74%
Sep 2024	53.73%	0.61%	0%	—	45.66%
Dec 2024	53.73%	0.59%	0.02%	—	45.65%
Mar 2025	53.73%	0.87%	0.02%	—	45.38%
Jun 2025	53.73%	0.51%	0.02%	—	45.73%
Sep 2025	53.73%	0.53%	0%	—	45.73%
Dec 2025	53.73%	0.52%	0.01%	—	45.75%
Mar 2026	53.73%	0.38%	0%	—	45.88%
Jun 2026	53.73%	0.31%	0%	—	45.95%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	9	76	39	17	140	57	14	9	61	140
Mar 2016	9	92	39	20	159	62	10	9	78	159
Mar 2017	9	114	39	17	178	61	21	9	88	178
Mar 2018	9	138	43	22	210	67	30	14	99	210
Mar 2019	9	171	38	23	240	101	0	28	111	240
Mar 2020	9	195	48	26	277	96	1	41	139	277
Mar 2021	9	229	16	29	282	87	4	44	148	282
Mar 2022	9	260	122	34	424	84	82	65	194	424
Mar 2023	9	284	164	89	546	108	149	65	224	546
Mar 2024	9	304	134	103	550	103	171	65	210	550
Mar 2025	9	331	104	103	546	105	183	65	193	546
Mar 2026	9	377	75	97	557	288	9	64	196	557

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	20	-12	-5	3
Mar 2016	19	-6	-12	1
Mar 2017	28	-15	-6	6
Mar 2018	32	-26	-6	0
Mar 2019	36	-25	-20	-9
Mar 2020	26	-21	-1	3
Mar 2021	41	-4	-41	-4
Mar 2022	16	-111	95	0
Mar 2023	33	-72	41	3
Mar 2024	43	-21	-24	-2
Mar 2025	64	-19	-46	-1
Mar 2026	51	-2	-48	0

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	72	95	79	86	70	96	80	95	118	110	103	115
Inventory Days	431	627	356	493	511	754	390	404	362	251	228	267
Days Payable	68	109	80	100	85	170	96	63	131	109	127	92
Cash Conversion Cycle	434	614	355	480	496	681	374	436	349	252	204	290
Working Capital Days	55	89	87	94	123	129	182	149	106	130	110	117
ROCE %	18%	22%	24%	26%	31%	20%	25%	17%	12%	9%	11%	16%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of HESTER BIOSCIENCES LTD (HESTERBIO)?

The reported market capitalisation for HESTER BIOSCIENCES LTD (HESTERBIO) is ₹1,819Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of HESTERBIO?

The current price shown for HESTER BIOSCIENCES LTD (HESTERBIO) on Fincrux is ₹2,129 with a 52-week high/low of ₹2,684/1,239.

What is the P/E ratio of HESTER BIOSCIENCES LTD (HESTERBIO)?

The stock P/E for HESTER BIOSCIENCES LTD (HESTERBIO) is 33.9 on Fincrux, with ROE at 13.0% and ROCE at 15.5%.

What were HESTERBIO latest quarterly results?

For Jun 2026, HESTER BIOSCIENCES LTD (HESTERBIO) reported sales ₹73 Cr and net profit ₹15 Cr (figures in ₹ crore unless noted).

What are HESTERBIO annual sales and net profit?

For TTM, HESTER BIOSCIENCES LTD (HESTERBIO) shows sales of ₹301 Cr and net profit of ₹59 Cr on the Fincrux profit & loss statement.

Who owns HESTER BIOSCIENCES LTD (HESTERBIO)?

Latest shareholding for HESTER BIOSCIENCES LTD (HESTERBIO) on Fincrux: Promoters 53.73% (Jun 2026), FIIs 0.31% (Jun 2026), DIIs 0.00% (Jun 2026), Public 45.95% (Jun 2026), No. of Shareholders 11,961% (Jun 2026).

Where can I find HESTER BIOSCIENCES LTD (HESTERBIO) financials?

HESTER BIOSCIENCES LTD (HESTERBIO) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show HESTERBIO balance sheet and cash flow?

Yes. The HESTER BIOSCIENCES LTD (HESTERBIO) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 13 October 2026 at 17:39